Fibroblast Delivery via Platelet-Rich Plasma for Wound Healing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Difficult-to-heal wounds, particularly in diabetic patients, face challenges due to impaired fibroblast proliferation, migration, and immune response, leading to delayed wound healing and chronic conditions.
Innovation Solution
Introduction of activated or inactivated fibroblasts and fibroblast-derived materials, such as extracellular vesicles, into wounds, either topically or subcutaneously, to stimulate proliferation, epithelialization, and tissue remodeling, potentially combined with growth factors and cytokines, to enhance wound healing.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If fibroblasts are introduced to stimulate wound healing, then wound closure rate improves, but treatment complexity increases
Solution Approach 1:
The patent uses platelet-rich plasma (PRP) as an intermediary carrier to deliver fibroblasts to the wound site. The PRP matrix protects fibroblasts during application, provides growth factors that enhance fibroblast activity, and simplifies the treatment procedure by combining cell delivery with a known effective wound healing adjunct. This resolves the contradiction by enabling effective fibroblast therapy while maintaining treatment simplicity through a single application step.
2Speed
If activated fibroblasts are used to accelerate healing, then healing speed improves, but immune response challenges increase
Solution Approach 1:
The patent employs the patient's own platelet-rich plasma as the delivery vehicle for fibroblasts, creating an autologous system that minimizes immune rejection. The PRP provides a biocompatible matrix that supports fibroblast survival and function while avoiding foreign body immune responses. This self-service approach allows accelerated healing through activated fibroblasts while circumventing immune response challenges through the use of the patient's own biological materials.
Data Source
AI summary
The present disclosure concerns use of activated or inactivated fibroblasts or fibroblast-derived materials, such as exosomes from fibroblasts, for wound care. The methods and compositions are useful for purpose of tissue differentiation, cell recruitment, differentiation of local stem cells, and expansion of local cells, such as keratocytes, vasal epithelial cells, myofibroblasts, and/or dermal fibroblasts, including for initiating and/or maintaining wound healing.